Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 1
Submit an article Journal homepage
1,397
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting

Anamaria Vera Jugrina IMS HEOR, Vilvoorde, Belgium
,
Volker Höselb StatSciConsult, Munich, Germany
,
Anastasia Ustyugovac Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
,
Maria De Francescoa IMS HEOR, Vilvoorde, Belgium
,
Mark Lamottea IMS HEOR, Vilvoorde, BelgiumCorrespondence[email protected]
&
Tom Sunderlandd Boehringer Ingelheim Ltd, Bracknell, UK
Pages 1-10 | Accepted 22 Jul 2015, Published online: 20 Aug 2015

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mark D. Danese, Michelle Gleeson, Robert I. Griffiths, David Catterick & Lucie Kutikova. (2017) Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United Kingdom. Journal of Medical Economics 20:9, pages 931-937.
Read now

Articles from other publishers (6)

Wei Xiong, Yunfeng Zhao, Song Liu, He Du, Yanmin Wang, Wenjie Li & Xuejun Guo. (2022) Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism. Frontiers in Pharmacology 13.
Crossref
Ayesha Javed, Muhammad Ajmal & Aaron Wolfson. (2021) Dabigatran in cardiovascular disease management: A comprehensive review. World Journal of Cardiology 13:12, pages 710-719.
Crossref
Vicky Mai, Laurent Bertoletti, Michel Cucherat, Sabine Jardel, Claire Grange, Steeve Provencher & Jean-Christophe Lega. (2019) Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. PLOS ONE 14:4, pages e0214134.
Crossref
Mohammad Al Mukdad, Daoud Al-Badriyeh & Hazem Fathy Elewa. (2019) Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961984910.
Crossref
Hamzeh Albaba, Charles Lim & Natasha B. Leighl. (2017) Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. PharmacoEconomics 35:12, pages 1195-1209.
Crossref
Lisa A. de Jong, Evgeni Dvortsin, Kristel J. Janssen & Maarten J. Postma. (2017) Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands. Clinical Therapeutics 39:2, pages 288-302.e4.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.